EPS for Fate Therapeutics, Inc. (FATE) Expected At $-0.27

October 14, 2018 - By Nellie Frank

Investors sentiment increased to 2.14 in 2018 Q2. Its up 0.06, from 2.08 in 2018Q1. It is positive, as 12 investors sold Fate Therapeutics, Inc. shares while 17 reduced holdings. 28 funds opened positions while 34 raised stakes. 39.35 million shares or 7.93% more from 36.46 million shares in 2018Q1 were reported.
Meeder Asset Mgmt holds 0% or 2,586 shares. 105,300 are owned by Schwab Charles Inv Mgmt Inc. Neuberger Berman Gru Limited Co reported 15,000 shares stake. Doheny Asset Ca invested in 0.18% or 29,635 shares. Susquehanna Interest Gp Llp invested in 0% or 22,895 shares. Dimensional Fund Lp holds 0% or 23,500 shares in its portfolio. Artal Sa holds 1.70 million shares or 0.41% of its portfolio. State Of Wisconsin Investment Board holds 0% or 50,600 shares in its portfolio. The New York-based Morgan Stanley has invested 0% in Fate Therapeutics, Inc. (NASDAQ:FATE). Wells Fargo Company Mn reported 117,623 shares. Moreover, California Pub Employees Retirement has 0% invested in Fate Therapeutics, Inc. (NASDAQ:FATE). The New York-based 683 Capital Mgmt Limited Liability Company has invested 0.57% in Fate Therapeutics, Inc. (NASDAQ:FATE). 83,268 were accumulated by Nuveen Asset Limited Com. Legal And General Group Plc owns 7,657 shares. Citigroup Inc accumulated 51,724 shares.

Analysts expect Fate Therapeutics, Inc. (NASDAQ:FATE) to report $-0.27 EPS on November, 7.They anticipate $0.01 EPS change or 3.85 % from last quarter’s $-0.26 EPS. After having $-0.37 EPS previously, Fate Therapeutics, Inc.’s analysts see -27.03 % EPS growth. The stock increased 1.58% or $0.21 during the last trading session, reaching $13.51. About 650,991 shares traded or 12.05% up from the average. Fate Therapeutics, Inc. (NASDAQ:FATE) has risen 181.90% since October 14, 2017 and is uptrending. It has outperformed by 166.28% the S&P500.

Fate Therapeutics, Inc. (NASDAQ:FATE) Ratings Coverage

Among 2 analysts covering Fate Therapeutics (NASDAQ:FATE), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Fate Therapeutics had 2 analyst reports since May 16, 2018 according to SRatingsIntel. The stock has “Buy” rating by Piper Jaffray on Wednesday, May 16.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company has market cap of $846.37 million. The Company’s immuno-oncology product candidates include FATE-NK100, a natural killer cell cancer immunotherapy that consists of adaptive memory NK cells; engineered hnCD16 induced pluripotent stem cells (iPSC)-derived natural killer cell therapy candidates for hematologic/solid tumors; and engineered chimeric antigen receptor iPSC-derived T cell therapy product candidates for hematologic/solid tumors. It currently has negative earnings. The company's immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and ToleraCyte for the treatment of autoimmune and inflammatory diseases; engineered iPSC-derived CD34+ cell therapy for immune disorders.

More notable recent Fate Therapeutics, Inc. (NASDAQ:FATE) news were published by: Nasdaq.com which released: “Fate Therapeutics Announces Pricing of Public Offering of Common Stock” on September 21, 2018, also Seekingalpha.com with their article: “Fate Therapeutics closes $144M equity offering” published on September 25, 2018, Globenewswire.com published: “Fate Therapeutics Appoints Wen Bo Wang, Ph.D. as Senior Vice President, Technical Operations” on October 04, 2018. More interesting news about Fate Therapeutics, Inc. (NASDAQ:FATE) were released by: Globenewswire.com and their article: “Fate Therapeutics to Present at Upcoming Investor Conferences” published on September 25, 2018 as well as Nasdaq.com‘s news article titled: “Fate Therapeutics Announces Strategic Collaboration with ONO Pharmaceutical to Develop Off-the-Shelf, iPSC …” with publication date: September 17, 2018.

Fate Therapeutics, Inc. (NASDAQ:FATE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News